Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
•Effectiveness of BIC/FTC/TAF was high among HIV late presenters starting ART•In this setting, BIC/FTC/TAF also demonstrated a good safety and tolerability profile•Among people starting ART with AIDS, BIC/FTC/TAF performance was even higher The efficacy of BIC/FTC/TAF in HIV late presenters initiati...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2024-01, Vol.63 (1), p.107016-107016, Article 107016 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107016 |
|---|---|
| container_issue | 1 |
| container_start_page | 107016 |
| container_title | International journal of antimicrobial agents |
| container_volume | 63 |
| creator | Corona, Diana Pérez-Valero, Ignacio Camacho, Angela Liarte, Ángela Gutiérrez Montero-Alonso, Marta Alemán, María Remedios Ruiz-Seco, Pilar González, Alexandre Pérez Riera, Melchor Jarrin, Inmaculada Rivero-Juárez, Antonio Rivero, Antonio |
| description | •Effectiveness of BIC/FTC/TAF was high among HIV late presenters starting ART•In this setting, BIC/FTC/TAF also demonstrated a good safety and tolerability profile•Among people starting ART with AIDS, BIC/FTC/TAF performance was even higher
The efficacy of BIC/FTC/TAF in HIV late presenters initiating ART has not been sufficiently evaluated.
The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment-naïve adult individuals from the CoRIS Cohort starting ART with CD4 counts |
| doi_str_mv | 10.1016/j.ijantimicag.2023.107016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153153768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S092485792300290X</els_id><sourcerecordid>2883585636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c461t-39764bd1ec6a7164f1bfedd354b31c3f3aac109bb52b5dc234123980e8e9be803</originalsourceid><addsrcrecordid>eNqNkU2LFDEQQIMo7rj6FyTevPRM0unuJEcZVndhwYt6DfmoLDV0p8ckM7D_3iyzijeFQEHVqxRVj5APnG0549PusMWDTRUX9PZh27NetLxslRdkw5XsO6m5eEk2TPdDp0apr8ibUg6M8VEM42tyJaTSTIphQ9xNjOArniFBKdSmQIuNUB_pGqlDX-Eh2zPmHSw1o8dqHSbYVUhrXFue2rnhyS4YgGKit3c_6Gwr0GOGAqlCLm_Jq2jnAu-e4zX5_vnm2_62u__65W7_6b7zw8RrJ7ScBhc4-MlKPg2RuwghiHFwgnsRhbWeM-3c2Lsx-F4MvBdaMVCgHSgmrsnHy7_HvP48QalmweJhnm2C9VSMaNu3Jyf1T7RXSoxqnMTUUH1BfV5LyRDNMeNi86PhzDzZMAfzlw3zZMNcbLTe989jTm6B8Kfz9_kbsL8A0O5yRsimeITkIWBuVkxY8T_G_ALdh6J-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2883585636</pqid></control><display><type>article</type><title>Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Corona, Diana ; Pérez-Valero, Ignacio ; Camacho, Angela ; Liarte, Ángela Gutiérrez ; Montero-Alonso, Marta ; Alemán, María Remedios ; Ruiz-Seco, Pilar ; González, Alexandre Pérez ; Riera, Melchor ; Jarrin, Inmaculada ; Rivero-Juárez, Antonio ; Rivero, Antonio</creator><creatorcontrib>Corona, Diana ; Pérez-Valero, Ignacio ; Camacho, Angela ; Liarte, Ángela Gutiérrez ; Montero-Alonso, Marta ; Alemán, María Remedios ; Ruiz-Seco, Pilar ; González, Alexandre Pérez ; Riera, Melchor ; Jarrin, Inmaculada ; Rivero-Juárez, Antonio ; Rivero, Antonio</creatorcontrib><description>•Effectiveness of BIC/FTC/TAF was high among HIV late presenters starting ART•In this setting, BIC/FTC/TAF also demonstrated a good safety and tolerability profile•Among people starting ART with AIDS, BIC/FTC/TAF performance was even higher
The efficacy of BIC/FTC/TAF in HIV late presenters initiating ART has not been sufficiently evaluated.
The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment-naïve adult individuals from the CoRIS Cohort starting ART with CD4 counts <200 cells/mm3 and/or AIDS-defining conditions between Jan 1, 2019 and Nov 30, 2020. Logistic regression models were used to estimate odds ratios (ORs) of association between initial regimen and achievement of viral suppression (VS) (primary objective), defined as HIV RNA <50 cop/ml, and immunological recovery (IR) (secondary objective), defined as CD4 count >200 cells/mm3, at weeks 24 and 48 after initiation of ART.
We evaluated 314 individuals (84.7% men, median age 40 years). Of them, 158 initiated with BIC/FTC/TAF. At inclusion, 117 had an AIDS-defining condition. In multivariable analyses, individuals with AIDS-defining conditions initiating ART with BIC/FTC/TAF achieved higher rates of VS at 24 weeks than other regimens (aOR: 0.2; 95%CI: 0.06 – 0.64) and, at 48 weeks than DTG/ABC/3TC (aOR: 0.06; 95%CI: 0.01 – 0.76) and DTG + TDF/3TC (aOR: 0.2; 95% CI: 0.47 – 0.9). No other differences in VS or IR were observed. At 24 and 48 weeks after ART initiation, treatment discontinuations were lower with BIC/FTC/TAF than with other regimens (3.2% and 7.6% vs. 24.4% and 37.8%, respectively; p<0.005).
Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters due to its high effectiveness and good tolerability.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2023.107016</identifier><identifier>PMID: 37890734</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acquired Immunodeficiency Syndrome - drug therapy ; Adult ; adults ; Alanine ; Amides ; Anti-HIV Agents - adverse effects ; antiretroviral agents ; Coris ; Drug Combinations ; Emtricitabine - adverse effects ; Female ; Heterocyclic Compounds, 3-Ring ; HIV Infections - drug therapy ; Humans ; Male ; Piperazines ; Pyridones ; regression analysis ; RNA ; Tenofovir - analogs & derivatives ; therapeutics</subject><ispartof>International journal of antimicrobial agents, 2024-01, Vol.63 (1), p.107016-107016, Article 107016</ispartof><rights>2023</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c461t-39764bd1ec6a7164f1bfedd354b31c3f3aac109bb52b5dc234123980e8e9be803</citedby><cites>FETCH-LOGICAL-c461t-39764bd1ec6a7164f1bfedd354b31c3f3aac109bb52b5dc234123980e8e9be803</cites><orcidid>0000-0002-8059-7171 ; 0000-0002-3488-7135 ; 0000-0003-0217-5122 ; 0000-0002-3432-5394</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S092485792300290X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37890734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Corona, Diana</creatorcontrib><creatorcontrib>Pérez-Valero, Ignacio</creatorcontrib><creatorcontrib>Camacho, Angela</creatorcontrib><creatorcontrib>Liarte, Ángela Gutiérrez</creatorcontrib><creatorcontrib>Montero-Alonso, Marta</creatorcontrib><creatorcontrib>Alemán, María Remedios</creatorcontrib><creatorcontrib>Ruiz-Seco, Pilar</creatorcontrib><creatorcontrib>González, Alexandre Pérez</creatorcontrib><creatorcontrib>Riera, Melchor</creatorcontrib><creatorcontrib>Jarrin, Inmaculada</creatorcontrib><creatorcontrib>Rivero-Juárez, Antonio</creatorcontrib><creatorcontrib>Rivero, Antonio</creatorcontrib><title>Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>•Effectiveness of BIC/FTC/TAF was high among HIV late presenters starting ART•In this setting, BIC/FTC/TAF also demonstrated a good safety and tolerability profile•Among people starting ART with AIDS, BIC/FTC/TAF performance was even higher
The efficacy of BIC/FTC/TAF in HIV late presenters initiating ART has not been sufficiently evaluated.
The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment-naïve adult individuals from the CoRIS Cohort starting ART with CD4 counts <200 cells/mm3 and/or AIDS-defining conditions between Jan 1, 2019 and Nov 30, 2020. Logistic regression models were used to estimate odds ratios (ORs) of association between initial regimen and achievement of viral suppression (VS) (primary objective), defined as HIV RNA <50 cop/ml, and immunological recovery (IR) (secondary objective), defined as CD4 count >200 cells/mm3, at weeks 24 and 48 after initiation of ART.
We evaluated 314 individuals (84.7% men, median age 40 years). Of them, 158 initiated with BIC/FTC/TAF. At inclusion, 117 had an AIDS-defining condition. In multivariable analyses, individuals with AIDS-defining conditions initiating ART with BIC/FTC/TAF achieved higher rates of VS at 24 weeks than other regimens (aOR: 0.2; 95%CI: 0.06 – 0.64) and, at 48 weeks than DTG/ABC/3TC (aOR: 0.06; 95%CI: 0.01 – 0.76) and DTG + TDF/3TC (aOR: 0.2; 95% CI: 0.47 – 0.9). No other differences in VS or IR were observed. At 24 and 48 weeks after ART initiation, treatment discontinuations were lower with BIC/FTC/TAF than with other regimens (3.2% and 7.6% vs. 24.4% and 37.8%, respectively; p<0.005).
Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters due to its high effectiveness and good tolerability.</description><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Adult</subject><subject>adults</subject><subject>Alanine</subject><subject>Amides</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>antiretroviral agents</subject><subject>Coris</subject><subject>Drug Combinations</subject><subject>Emtricitabine - adverse effects</subject><subject>Female</subject><subject>Heterocyclic Compounds, 3-Ring</subject><subject>HIV Infections - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Piperazines</subject><subject>Pyridones</subject><subject>regression analysis</subject><subject>RNA</subject><subject>Tenofovir - analogs & derivatives</subject><subject>therapeutics</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2LFDEQQIMo7rj6FyTevPRM0unuJEcZVndhwYt6DfmoLDV0p8ckM7D_3iyzijeFQEHVqxRVj5APnG0549PusMWDTRUX9PZh27NetLxslRdkw5XsO6m5eEk2TPdDp0apr8ibUg6M8VEM42tyJaTSTIphQ9xNjOArniFBKdSmQIuNUB_pGqlDX-Eh2zPmHSw1o8dqHSbYVUhrXFue2rnhyS4YgGKit3c_6Gwr0GOGAqlCLm_Jq2jnAu-e4zX5_vnm2_62u__65W7_6b7zw8RrJ7ScBhc4-MlKPg2RuwghiHFwgnsRhbWeM-3c2Lsx-F4MvBdaMVCgHSgmrsnHy7_HvP48QalmweJhnm2C9VSMaNu3Jyf1T7RXSoxqnMTUUH1BfV5LyRDNMeNi86PhzDzZMAfzlw3zZMNcbLTe989jTm6B8Kfz9_kbsL8A0O5yRsimeITkIWBuVkxY8T_G_ALdh6J-</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Corona, Diana</creator><creator>Pérez-Valero, Ignacio</creator><creator>Camacho, Angela</creator><creator>Liarte, Ángela Gutiérrez</creator><creator>Montero-Alonso, Marta</creator><creator>Alemán, María Remedios</creator><creator>Ruiz-Seco, Pilar</creator><creator>González, Alexandre Pérez</creator><creator>Riera, Melchor</creator><creator>Jarrin, Inmaculada</creator><creator>Rivero-Juárez, Antonio</creator><creator>Rivero, Antonio</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0002-8059-7171</orcidid><orcidid>https://orcid.org/0000-0002-3488-7135</orcidid><orcidid>https://orcid.org/0000-0003-0217-5122</orcidid><orcidid>https://orcid.org/0000-0002-3432-5394</orcidid></search><sort><creationdate>20240101</creationdate><title>Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters</title><author>Corona, Diana ; Pérez-Valero, Ignacio ; Camacho, Angela ; Liarte, Ángela Gutiérrez ; Montero-Alonso, Marta ; Alemán, María Remedios ; Ruiz-Seco, Pilar ; González, Alexandre Pérez ; Riera, Melchor ; Jarrin, Inmaculada ; Rivero-Juárez, Antonio ; Rivero, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c461t-39764bd1ec6a7164f1bfedd354b31c3f3aac109bb52b5dc234123980e8e9be803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Adult</topic><topic>adults</topic><topic>Alanine</topic><topic>Amides</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>antiretroviral agents</topic><topic>Coris</topic><topic>Drug Combinations</topic><topic>Emtricitabine - adverse effects</topic><topic>Female</topic><topic>Heterocyclic Compounds, 3-Ring</topic><topic>HIV Infections - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Piperazines</topic><topic>Pyridones</topic><topic>regression analysis</topic><topic>RNA</topic><topic>Tenofovir - analogs & derivatives</topic><topic>therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Corona, Diana</creatorcontrib><creatorcontrib>Pérez-Valero, Ignacio</creatorcontrib><creatorcontrib>Camacho, Angela</creatorcontrib><creatorcontrib>Liarte, Ángela Gutiérrez</creatorcontrib><creatorcontrib>Montero-Alonso, Marta</creatorcontrib><creatorcontrib>Alemán, María Remedios</creatorcontrib><creatorcontrib>Ruiz-Seco, Pilar</creatorcontrib><creatorcontrib>González, Alexandre Pérez</creatorcontrib><creatorcontrib>Riera, Melchor</creatorcontrib><creatorcontrib>Jarrin, Inmaculada</creatorcontrib><creatorcontrib>Rivero-Juárez, Antonio</creatorcontrib><creatorcontrib>Rivero, Antonio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Corona, Diana</au><au>Pérez-Valero, Ignacio</au><au>Camacho, Angela</au><au>Liarte, Ángela Gutiérrez</au><au>Montero-Alonso, Marta</au><au>Alemán, María Remedios</au><au>Ruiz-Seco, Pilar</au><au>González, Alexandre Pérez</au><au>Riera, Melchor</au><au>Jarrin, Inmaculada</au><au>Rivero-Juárez, Antonio</au><au>Rivero, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>63</volume><issue>1</issue><spage>107016</spage><epage>107016</epage><pages>107016-107016</pages><artnum>107016</artnum><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>•Effectiveness of BIC/FTC/TAF was high among HIV late presenters starting ART•In this setting, BIC/FTC/TAF also demonstrated a good safety and tolerability profile•Among people starting ART with AIDS, BIC/FTC/TAF performance was even higher
The efficacy of BIC/FTC/TAF in HIV late presenters initiating ART has not been sufficiently evaluated.
The aim of this study was to assess the effectiveness and tolerability of BIC/FTC/TAF compared to other first-line antiretroviral regimens in treatment-naïve adult individuals from the CoRIS Cohort starting ART with CD4 counts <200 cells/mm3 and/or AIDS-defining conditions between Jan 1, 2019 and Nov 30, 2020. Logistic regression models were used to estimate odds ratios (ORs) of association between initial regimen and achievement of viral suppression (VS) (primary objective), defined as HIV RNA <50 cop/ml, and immunological recovery (IR) (secondary objective), defined as CD4 count >200 cells/mm3, at weeks 24 and 48 after initiation of ART.
We evaluated 314 individuals (84.7% men, median age 40 years). Of them, 158 initiated with BIC/FTC/TAF. At inclusion, 117 had an AIDS-defining condition. In multivariable analyses, individuals with AIDS-defining conditions initiating ART with BIC/FTC/TAF achieved higher rates of VS at 24 weeks than other regimens (aOR: 0.2; 95%CI: 0.06 – 0.64) and, at 48 weeks than DTG/ABC/3TC (aOR: 0.06; 95%CI: 0.01 – 0.76) and DTG + TDF/3TC (aOR: 0.2; 95% CI: 0.47 – 0.9). No other differences in VS or IR were observed. At 24 and 48 weeks after ART initiation, treatment discontinuations were lower with BIC/FTC/TAF than with other regimens (3.2% and 7.6% vs. 24.4% and 37.8%, respectively; p<0.005).
Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters due to its high effectiveness and good tolerability.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>37890734</pmid><doi>10.1016/j.ijantimicag.2023.107016</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8059-7171</orcidid><orcidid>https://orcid.org/0000-0002-3488-7135</orcidid><orcidid>https://orcid.org/0000-0003-0217-5122</orcidid><orcidid>https://orcid.org/0000-0002-3432-5394</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2024-01, Vol.63 (1), p.107016-107016, Article 107016 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3153153768 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acquired Immunodeficiency Syndrome - drug therapy Adult adults Alanine Amides Anti-HIV Agents - adverse effects antiretroviral agents Coris Drug Combinations Emtricitabine - adverse effects Female Heterocyclic Compounds, 3-Ring HIV Infections - drug therapy Humans Male Piperazines Pyridones regression analysis RNA Tenofovir - analogs & derivatives therapeutics |
| title | Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T17%3A27%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20safety%20of%20bictegravir/emtricitabine/tenofovir%20alafenamide%20in%20HIV%20late%20presenters&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Corona,%20Diana&rft.date=2024-01-01&rft.volume=63&rft.issue=1&rft.spage=107016&rft.epage=107016&rft.pages=107016-107016&rft.artnum=107016&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2023.107016&rft_dat=%3Cproquest_cross%3E2883585636%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2883585636&rft_id=info:pmid/37890734&rft_els_id=S092485792300290X&rfr_iscdi=true |